GlassScriptPhysician profile
Demetrius S Maoury
NPI 1619941796
$3,517.61
in general payments reported to CMS, 2019-2025
34 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $248 · 2021: $706 · 2022: $553 · 2023: $527 · 2024: $497 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.30 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.71 | 2021-2025 | |
| Novo Nordisk INC | $677.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $315.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $256.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $158.27 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $155.04 | 2019-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $152.82 | 2023-2025 | Veozah, Myrbetriq |
| Amgen INC. | $151.68 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $142.05 | 2019-2024 | Jardiance |
| Welch Allyn | $120.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.77 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $66.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.71 | 2021-2025 | Jardiance |
| Ibsa Pharma INC. | $41.83 | 2021-2022 | |
| Amarin Pharma, INC. | $40.40 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $34.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.15 | 2023-2024 | |
| Antares Pharma, INC. | $29.83 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Kowa Pharmaceuticals America, INC. | $27.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.70 | 2022 | |
| Abbott Laboratories | $20.86 | 2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $20.63 | 2023 | Varithena Administration Pack |
| Eisai INC. | $17.91 | 2021 | |
| Hologic Sales and Service, LLC | $16.38 | 2022 | |
| Esperion Therapeutics, INC. | $15.33 | 2021 | |
| Currax Pharmaceuticals LLC | $14.86 | 2023 | Contrave |
| Phathom Pharmaceuticals, INC. | $14.48 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $14.45 | 2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $14.36 | 2022 | |
| Sumitomo Pharma America, INC. | $14.30 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.36 | 2021 | |
| Clarus Therapeutics INC. | $11.95 | 2021 | |
| Dexcom, INC. | $11.86 | 2021 | |
| Merck Sharp & Dohme LLC | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demetrius Maoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.